PROTHENA CORPORATION PUBLIC LIMITED COMPANY Payments for Repurchase of Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY payments for repurchase of equity for the quarter ending 2026-06-30 was $15.57M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY payments for repurchase of equity for the quarter ending 2026-03-31 was $6.95M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY payments for repurchase of equity for the quarter ending 2025-06-30 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY payments for repurchase of equity for the quarter ending 2025-03-31 was $0.00.
| Period end | Payments for Repurchase of Equity 3 month | Payments for Repurchase of Equity 12 month |
|---|---|---|
| 2026-06-30 | $15.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | $6.95M 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |